Filing Flows › Guardant Health (GH) › Oncology revenue
Guardant Health (GH) Oncology revenue by quarter
Guardant Health's Oncology revenue was $231M in Q3 2026 (third quarter 2026), +6% from Q2 2026. Over the last 7 quarters it ranged from $151M (Q1 2025) to $231M (Q3 2026).
| Quarter | Oncology revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $231M | +6% | +25% |
| Q2 2026 | $219M | +7% | +38% |
| Q1 2026 | $205M | +8% | +36% |
| Q4 2025 | $190M | +3% | — |
| Q3 2025 | $184M | +16% | — |
| Q2 2025 | $159M | +5% | — |
| Q1 2025 | $151M | — | — |
Q3 2026 at a glance
Guardant Health, Q3 2026: revenue $361M (+36% year over year), operating margin -36.8%, net loss $124M, operating cash flow −$23.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Guardant Health's Oncology revenue?
Guardant Health's Oncology revenue was $231M in Q3 2026 (third quarter 2026), +6% from Q2 2026.
How has Guardant Health's Oncology revenue changed?
Over the last 7 quarters it ranged from $151M (Q1 2025) to $231M (Q3 2026).